Eli Lilly and Co (WBO:LLYC) Policyholder Funds

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:LLYC Eli Lilly and Co WBO:LLYC
81 GF Score
Price €1,015.60
GF Value €1,376.23
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Eli Lilly and Co Policyholder Funds?

Policyholder Funds only applies to insurance companies.

WBO:LLYC
81GF Score
Eli Lilly and Co WBO:LLYC
Policyholder Funds is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (WBO:LLYC) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,015.60 is trading 26.2% below its estimated GF Value™ of €1,376.23. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for WBO:LLYC:

  • Policyholder Funds:
  • GF Value™: €1,376.23 vs. price of €1,015.60 (26.2% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the WBO:LLYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in a single business segment, with medicines sold in approximately 90 countries. Its cardiometabolic health franchise leads the portfolio, anchored by the incretin medicines Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea, alongside Trulicity, Jardiance, and insulins. Other therapeutic areas include oncology (Verzenio for breast cancer, Jaypirca, Retevmo), immunology (Taltz, Omvoh, Ebglyss), and neuroscience (Kisunla for early Alzheimer's disease, Emgality for migraine). Founded in 1876 and incorporated in Indiana in 1901, Lilly manufactures and distributes through facilities in the United States, Europe, and Asia and continues to invest heavily in expanding manufacturing capacity for its incretin medicines.
81GF Score

Get the complete analysis for WBO:LLYC

Policyholder Funds is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,015.60
Price
€1,376.23
GF Value